Abstract
Early detection, right therapeutic intervention, and simultaneous effectiveness mapping are considered the critical factors in successful cancer therapy. Nevertheless, these factors experience the limitations of conventional cancer diagnostics and therapeutics delivery approaches. Along with providing the targeted therapeutics delivery, advances in nanomedicines have allowed the combination of therapy and diagnostics in a single system (called cancer theranostics). This paper discusses the progress in the pre-clinical and clinical development of therapeutics, diagnostics, and theranostics cancer nanomedicines. It has been well evident that compared to the overabundance of works that claimed success in pre-clinical studies, merely 15 and around 75 cancer nanomedicines are approved, and currently under clinical trials, respectively. Thus, we also brief the critical bottlenecks in the successful clinical translation of cancer nanomedicines.
Highlights
Cancer remains a significantly complex and challenging disease globally
This paper provides a comprehensive account of the progress made over the years in cancer nanomedicines as diagnostics, therapeutics, and theranostics
Fluorescence imaging via carbon dots (CDs) has found multifunctional applications in cancer imaging, drug delivery as well as tracking response of the therapy
Summary
Cancer remains a significantly complex and challenging disease globally. It has been estimated that in the year 2018, the number of new cancer patients and the cancers-associated deaths reached 18.1 million and 9.6 million, respectively. Nanomedicines advances over the years offer preferential chemotherapeutics delivery to tumors while un-exposing the healthy tissues and minimizing the side effects of chemotherapy and imaging agents. Nanoparticle design that can combine the diagnosis and therapy in a single carrier or system (termed as theranostics) [7]. Safer, and effective cancer therapy and remains a significant research area by cancer nanotechnology and biomedical researchers. Numerous research discussed the development and theranostic cancer nanomedicines [8,9]. This paper provides a comprehensive account of the progress made over the years in cancer nanomedicines as diagnostics, therapeutics, and theranostics.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call